509 related articles for article (PubMed ID: 9676215)
21. Repeat prostate needle biopsy: who needs it?
Ellis WJ; Brawer MK
J Urol; 1995 May; 153(5):1496-8. PubMed ID: 7536254
[TBL] [Abstract][Full Text] [Related]
22. Volume-adjusted prostate-specific antigen (PSA) variables in detecting impalpable prostate cancer in men with PSA levels of 2-4 ng/mL: transabdominal measurement makes a significant contribution.
Kobayashi T; Kawahara T; Nishizawa K; Ogura K; Mitsumori K; Ide Y
BJU Int; 2005 Jun; 95(9):1245-8. PubMed ID: 15892809
[TBL] [Abstract][Full Text] [Related]
23. Contrast-enhanced gray-scale transrectal ultrasound-guided prostate biopsy in men with elevated serum prostate-specific antigen levels.
Yang JC; Tang J; Li J; Luo Y; Li Y; Shi H
Acad Radiol; 2008 Oct; 15(10):1291-7. PubMed ID: 18790401
[TBL] [Abstract][Full Text] [Related]
24. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
[TBL] [Abstract][Full Text] [Related]
25. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate specific antigen levels < or = 10 ng/mL.
Garzotto M; Hudson RG; Peters L; Hsieh YC; Barrera E; Mori M; Beer TM; Klein T
Cancer; 2003 Oct; 98(7):1417-22. PubMed ID: 14508828
[TBL] [Abstract][Full Text] [Related]
26. Prostate cancer detection in men with prostate specific antigen 4 to 10 ng/ml using a combined approach of contrast enhanced color Doppler targeted and systematic biopsy.
Pelzer A; Bektic J; Berger AP; Pallwein L; Halpern EJ; Horninger W; Bartsch G; Frauscher F
J Urol; 2005 Jun; 173(6):1926-9. PubMed ID: 15879783
[TBL] [Abstract][Full Text] [Related]
27. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
[TBL] [Abstract][Full Text] [Related]
28. [Diagnostic value of 10 systematized and ultrasound-guided transrectal prostatic biopsies].
Ravery V; Billebaud T; Toublanc M; Boccon-Gibod L; Hermieu JF; Moulinier F; Blanc E; Delmas V; Boccon-Gibod L
Prog Urol; 1998 Dec; 8(6):1012-7. PubMed ID: 9894260
[TBL] [Abstract][Full Text] [Related]
29. Examination of the 3 molecular forms of serum prostate specific antigen for distinguishing negative from positive biopsy: relationship to transition zone volume.
Stamey TA; Yemoto CE
J Urol; 2000 Jan; 163(1):119-26. PubMed ID: 10604328
[TBL] [Abstract][Full Text] [Related]
30. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
31. A role of multifactorial evaluation of prostatic 3T MRI in patients with elevated prostatic-specific antigen levels: prospective comparison with ultrasound-guided transrectal biopsy.
Ferda J; Kastner J; Hora M; Hes O; Fínek J; Topolčan O; Kreuzberg B
Anticancer Res; 2013 Jun; 33(6):2791-5. PubMed ID: 23749943
[TBL] [Abstract][Full Text] [Related]
32. [Screening of prostate carcinoma].
Trinkler FB
Ther Umsch; 1995 Jun; 52(6):393-8. PubMed ID: 7541568
[TBL] [Abstract][Full Text] [Related]
33. Effect of intra-observer variation in prostate volume measurement on prostate-specific antigen density calculations among prostate cancer active surveillance participants.
Ko JS; Landis P; Carter HB; Partin AW
BJU Int; 2011 Dec; 108(11):1739-42. PubMed ID: 21736692
[TBL] [Abstract][Full Text] [Related]
34. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Littrup PJ
Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
[TBL] [Abstract][Full Text] [Related]
35. The case for prostate cancer screening.
Andriole GL
Semin Urol; 1993 May; 11(2):50-3. PubMed ID: 7689738
[TBL] [Abstract][Full Text] [Related]
36. The diagnostic accuracy of the age-adjusted and prostate volume-adjusted biopsy method in males with prostate specific antigen levels of 4.1-10.0 ng/mL.
Ito K; Ohi M; Yamamoto T; Miyamoto S; Kurokawa K; Fukabori Y; Suzuki K; Yamanaka H
Cancer; 2002 Nov; 95(10):2112-9. PubMed ID: 12412164
[TBL] [Abstract][Full Text] [Related]
37. The change in serum Thiol/Disulphide homeostasis after transrectal ultrasound guided prostate biopsy.
Tokgöz H; Taş S; Giray Ö; Yalçınkaya S; Tokgöz Ö; Koca C; Savaş M; Erel Ö
Int Braz J Urol; 2017; 43(3):455-461. PubMed ID: 28128906
[TBL] [Abstract][Full Text] [Related]
38. Transrectal biopsy of the prostate guided by transrectal ultrasound.
Torp-Pedersen ST; Lee F
Urol Clin North Am; 1989 Nov; 16(4):703-12. PubMed ID: 2683300
[TBL] [Abstract][Full Text] [Related]
39. Use of transrectal ultrasound and prostate-specific antigen in diagnosis of prostatic intraepithelial neoplasia.
Lee F; Torp-Pedersen ST; Carroll JT; Siders DB; Christensen-Day C; Mitchell AE
Urology; 1989 Dec; 34(6 Suppl):4-8. PubMed ID: 2481362
[TBL] [Abstract][Full Text] [Related]
40. [Clinical utility of available diagnostic tests in prostatic carcinoma. Results of 500 biopsies. I. PSA, PSA density, and predicted PSA].
Rodríguez Rodríguez R; Mayayo Dehesa T; Galbis Sanjuan F; Jiménez Cidre M; Burgos Revilla FJ; Allona Almagro A; Gomez dos Santos V
Arch Esp Urol; 1997 May; 50(4):333-8. PubMed ID: 9313041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
